The Monaldi Archives for Chest Disease, published by PAGEPRESS PUBL, is a vital resource for researchers and healthcare professionals dedicated to the fields of cardiology and pulmonary medicine. With an ISSN of 1122-0643 and an E-ISSN of 2532-5264, this Open Access journal has been committed to disseminating high-quality research since 2004, ensuring that findings in chest disease are easily accessible to a global audience. Based in Italy, the journal features contributions that reflect a broad scope of topics within its fields, achieving a Q3 ranking in both Cardiology and Cardiovascular Medicine, as well as in Pulmonary and Respiratory Medicine as of 2023. The journal's Scopus ranks place it at 168th out of 387 in its cardiology category and 83rd out of 155 in pulmonary medicine, indicating its relevance in the academic landscape. With its commitment to advancing knowledge and practice, the Monaldi Archives for Chest Disease stands as an essential platform for publication and dialogue in chest disease research, appealing to a diverse audience of scholars and practitioners.

Respiratory Medicine is a leading journal in the field of pulmonary and respiratory medicine, dedicated to advancing knowledge and research from 1989 to 2024. Published by W B Saunders Co Ltd, this esteemed journal is recognized for its high impact, reflected in its Q1 quartile ranking in 2023 within the category of Pulmonary and Respiratory Medicine and its impressive Scopus ranking of 27 out of 155 journals, placing it in the 82nd percentile. With a focus on publishing groundbreaking research, comprehensive reviews, and innovative practices, Respiratory Medicine serves as an essential resource for health professionals, researchers, and students aiming to improve patient outcomes and understand complex respiratory conditions. While the journal is not Open Access, its contributions to the scientific community are invaluable, providing insights that drive both academic and clinical advancements in respiratory health.

Respiratory Investigation is a leading peer-reviewed journal published by Elsevier, dedicated to advancing the field of Pulmonary and Respiratory Medicine. Since its inception in 2012, the journal has grown to become a vital resource for researchers, clinicians, and students alike, providing a platform for high-quality research articles, reviews, and clinical studies. With a commendable impact factor and ranked in the Q2 category of Scopus' 2023 metrics, it stands at rank #57 out of 155 in its field, illustrating its importance and influence within the academic community. Although the journal operates on a subscription basis, it remains committed to disseminating essential findings that enhance the understanding and treatment of respiratory diseases. Set against the innovative backdrop of the Netherlands, Respiratory Investigation not only serves as a conduit for scholarly exchange but also plays a critical role in shaping future research directions and clinical practices.

Thoracic Research and Practice is an emerging open access journal published by AVES that aims to advance knowledge in the field of pulmonary and respiratory medicine. Launched in 2022, this journal aspires to provide a platform for innovative research, clinical practices, and advancements in thoracic health. With an E-ISSN of 2979-9139, it caters to a global audience while based in Turkey. Although it currently holds a Q4 category in the 2023 ranking within its field, the journal is dedicated to improving its standing through the inclusion of high-quality, original articles, systematic reviews, and case studies. As it converges years from 2023 to 2024, Thoracic Research and Practice invites researchers, professionals, and students to contribute valuable insights that aim to enhance patient outcomes and propel further exploration in this critical area of medicine.

Tuberculosis and Respiratory Diseases is a leading open-access journal published by THE KOREAN ACADEMY OF TUBERCULOSIS & RESPIRATORY DISEASES, dedicated to disseminating knowledge in the fields of infectious diseases and pulmonary medicine. Since its inception in 1980, the journal has undergone significant growth, currently recognized in the elite Q2 category for both Infectious Diseases and Pulmonary and Respiratory Medicine as of 2023. With an impact factor reflecting its esteemed position—ranked 52nd in its category—it serves as a vital resource for researchers and healthcare professionals seeking cutting-edge insights, studies, and advancements in the management and treatment of respiratory diseases, particularly tuberculosis. The journal is committed to providing open access to its content since 2013, ensuring that critical research is available to scholars worldwide, fostering collaboration and innovation in the global fight against respiratory illnesses.

Welcome to the Journal of Thoracic Disease, a premier scholarly journal dedicated to advancing the field of pulmonary and respiratory medicine. Published by AME PUBLISHING COMPANY in Hong Kong, this journal has established itself as a critical platform for the dissemination of innovative research and clinical advancements since its inception in 2009. With an impressive Q2 ranking in the Scopus category of Pulmonary and Respiratory Medicine, it is recognized for its contribution to the academic community, featuring a broad range of original research, reviews, and case studies that address contemporary challenges in thoracic disease management. The journal is committed to Open Access principles, ensuring that high-quality research is readily available to a global audience, further enhancing its impact factor and reach. Researchers, healthcare professionals, and students alike will find invaluable insights within its pages, making Journal of Thoracic Disease an essential resource for those invested in the respiratory health domain.

Pulmonology, an esteemed journal published by Elsevier, serves as a vital platform for advancing knowledge in the field of Pulmonary and Respiratory Medicine. Since its transition to Open Access in 2018, this journal has successfully fostered a global readership, allowing for unrestricted dissemination of cutting-edge research. With an impressive Scopus ranking of #8 out of 155 in its category and a notable 2023 Q1 status, Pulmonology consistently showcases high-quality studies and reviews that contribute to the understanding and treatment of respiratory disorders. Authors and readers alike benefit from its commitment to publish influential research that addresses contemporary challenges in lung health. By bridging the gap between theory and clinical practice, the journal paves the way for innovative practices in pulmonology, making it an indispensable resource for researchers, healthcare professionals, and students interested in this dynamic field.

The Lancet Respiratory Medicine, published by Elsevier in the United Kingdom, is a premier journal dedicated to the field of pulmonary and respiratory medicine. With its impressive impact factor and a prestigious ranking of #1 out of 155 in its category as of 2023, it holds a remarkable position in advancing research and clinical practices in respiratory health. The journal invites original research, reviews, and clinical studies that aim to propel the understanding of respiratory diseases, fostering innovations in treatment and management strategies. Operating under a Q1 category in Scopus rankings, it is an essential platform for researchers, healthcare professionals, and students who are committed to enhancing patient care and advancing knowledge in this crucial area of medicine. The Lancet Respiratory Medicine remains a vital resource for the latest findings and discussions shaping the future of respiratory health.

Tuberkuloz ve Toraks (Tuberculosis and Thorax) is a distinguished journal published by the TURKISH ASSOCIATION OF TUBERCULOSIS AND THORAX located in Turkey. Serving as a pivotal platform for researchers and practitioners in the fields of Critical Care, Intensive Care Medicine, and Pulmonary and Respiratory Medicine, this journal has been disseminating vital research since 2003 and is committed to advancing knowledge and clinical practices related to tuberculosis and thoracic diseases. Although currently not an Open Access publication, its relevance is underscored by its rankings within Scopus, including a Q3 category in Critical Care and Intensive Care Medicine and a Q4 in Pulmonary and Respiratory Medicine, reflecting its significant contributions to the academic community. With a mission to foster the exchange of innovative ideas and encourage rigorous scholarly discourse, Tuberkuloz ve Toraks plays an essential role in addressing pressing health challenges associated with respiratory ailments and remains an invaluable resource for researchers, health professionals, and students dedicated to improving outcomes in thoracic health.

Welcome to the Indian Journal of Respiratory Care, a premier platform dedicated to advancing research and clinical practices in the field of respiratory health. Published by JAYPEE BROTHERS MEDICAL PUBLISHERS PVT LTD, this journal has established itself as a crucial resource for researchers, healthcare professionals, and educators since embracing an Open Access model in 2012, ensuring maximum visibility and accessibility of vital research findings. The journal aims to disseminate high-quality articles encompassing a wide range of topics, including but not limited to, respiratory diseases, pulmonary care, and innovative treatment approaches. With its commitment to fostering collaboration and knowledge exchange, the Indian Journal of Respiratory Care is poised to make a significant impact in the ever-evolving landscape of respiratory medicine. As the field continues to grow, this journal serves as an essential touchpoint for those invested in enhancing patient care and outcomes.